Unless otherwise defined, the abbreviations and definitions used in the announcements dated 14 August 2020 and 18 September 2020 shall apply herein.

Reference is made to the Ho Wah Genting Berhad’s (“HWGB” or the “Company”) announcement on 18 September 2020, whereby the Company had been informed by E-MO Biology Inc. (“EBI”) that it had entered into agreements with Black Diamond, Roderick A. Comunale II MD Inc. and America Diagnostics & Genescan Diagnostics Inc. for the purposes stated therein in the announcement.

The Board of Directors of HWGB is pleased to announce that following the approval from U.S. Food and Drug Administration being obtained on 28 October 2020 by EBI to commence its Phase IV clinical research study on the effectiveness of poliomyelitis virus vaccine for prevention of COVID-19, EBI had on 14 November 2020 entered into a new Clinical Trial Agreement (“New CTA”) with Roderick A. Comunale II MD Inc which supersedes the previous Clinical Trial Agreement entered into as announced on 18 September 2020 (“Initial CTA”).

For information purposes, the comparison of the key revised terms contained in the New CTA and the terms set out in the Initial CTA are summarized below:

This announcement is dated 16 November 2020.